Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals
New developments reported by Alnylam Pharmaceuticals officials
February 14th, 2007
New developments reported by Alnylam Pharmaceuticals officials. This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals. Report 1: Alnylam Pharmaceuticals, Inc. (ALNY) announced its intention to offer and sell approximately 4,700,000 shares of common stock in a public offering. The offering is underwritten by Banc of America Securities LLC. Alnylam also intends to grant the underwriter a thirty-day option to purchase up to approximately 705,000 additional shares. Alnylam is a leading biopharmaceutical company developing novel therapeutics...
Source: Medical Patent Law Weekly (2007-02-14)
|
